Britannia Life Sciences Inc.
BLAB
CNSX
| 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | 12/31/2023 | |
|---|---|---|---|---|---|
| Revenue | -6.72% | -7.27% | -11.24% | 5.45% | 9.32% |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -6.72% | -7.27% | -11.24% | 5.45% | 9.32% |
| Cost of Revenue | 16.74% | 5.69% | 17.20% | 90.49% | 43.61% |
| Gross Profit | -18.46% | -12.48% | -20.51% | -36.78% | -2.34% |
| SG&A Expenses | -2.00% | -37.45% | 18.66% | -55.68% | 35.27% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 4.36% | -22.97% | 18.12% | 2.55% | 37.99% |
| Operating Income | -602.88% | 84.34% | -74.12% | 19.77% | -91.02% |
| Income Before Tax | -108.66% | -202.93% | -386.40% | -1,479.05% | 102.62% |
| Income Tax Expenses | 19.13% | 5.47% | -108.33% | -43.96% | -29.75% |
| Earnings from Continuing Operations | -128.00% | -240.79% | -855.16% | -882.54% | 183.47% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -119.84% | -247.26% | 67.69% | -127.72% | 220.97% |
| Net Income | -124.85% | -262.22% | -515.75% | -1,149.62% | 1,083.75% |
| EBIT | -602.88% | 84.34% | -74.12% | 19.77% | -91.02% |
| EBITDA | -238.49% | 56.01% | -73.20% | 9.69% | -76.22% |
| EPS Basic | -125.00% | -263.64% | -560.00% | -1,138.46% | 1,300.00% |
| Normalized Basic EPS | -233.33% | -241.67% | -475.00% | -4,475.00% | 118.75% |
| EPS Diluted | -125.00% | -263.64% | -560.00% | -1,138.46% | 1,300.00% |
| Normalized Diluted EPS | -233.33% | -241.67% | -475.00% | -4,475.00% | 118.75% |
| Average Basic Shares Outstanding | 0.00% | 0.00% | 0.00% | 0.00% | 0.03% |
| Average Diluted Shares Outstanding | 0.00% | 0.00% | 0.00% | 0.00% | 0.03% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |